Up to your usual tricks, Harvett?
Rasul: The majority of patients were previously treated with abiraterone/enzalutamide (69%) and docetaxel/cabazitaxel (67%)
LuPIN: All patients had received and failed two prior lines of therapy (chemotherapy and androgen signalling inhibitors) and most patients (29/32) had failed a third line of therapy (another chemotherapy) prior to entering the trial.
These trials have wildly different patient criteria. You should include a disclaimer with your posts, to acknowledge your unbalanced views.
- Forums
- ASX - By Stock
- Ann: Pronounced survival benefit in LuPIN interim trial data
Up to your usual tricks, Harvett? Rasul: The majority of...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.0¢ |
Change
0.010(10.0%) |
Mkt cap ! $32.14M |
Open | High | Low | Value | Volume |
10.5¢ | 11.5¢ | 10.5¢ | $19.51K | 177.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 47475 | 10.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.5¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 47475 | 0.105 |
3 | 90006 | 0.100 |
1 | 100000 | 0.098 |
2 | 105340 | 0.097 |
2 | 20728 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.115 | 10000 | 1 |
0.120 | 86272 | 4 |
0.125 | 136094 | 2 |
0.130 | 340769 | 6 |
0.135 | 399760 | 2 |
Last trade - 15.41pm 18/09/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |